Provided by Tiger Fintech (Singapore) Pte. Ltd.

Indaptus Therapeutics, Inc.

2.91
-0.3930-11.90%
Post-market: 2.74-0.1700-5.84%19:13 EDT
Volume:985.74K
Turnover:3.10M
Market Cap:3.22M
PE:-0.07
High:3.81
Open:3.13
Low:2.50
Close:3.30
52wk High:58.24
52wk Low:2.50
Shares:1.11M
Float Shares:850.70K
Volume Ratio:24.63
T/O Rate:115.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-40.9385
EPS(LYR):-44.9582
ROE:-755.04%
ROA:-136.55%
PB:-1.92
PE(LYR):-0.06

Loading ...

Investors Await Key Jobs Data as US Futures Mixed in Friday's Premarket

MT Newswires Live
·
Sep 05

Indaptus Therapeutics Announces Promising Updates on Decoy20 and Tislelizumab Combination Therapy in Ongoing Clinical Trial

Reuters
·
Sep 05

Indaptus Therapeutics Inc - Decoy20 Monotherapy Induces Partial Response in Cancer Patient

THOMSON REUTERS
·
Sep 05

Indaptus Therapeutics Inc - Decoy20 Combination With Pd-1 Inhibitor Shows Consistent Safety

THOMSON REUTERS
·
Sep 05

Indaptus Therapeutics: Files for Mixed Shelf Offering of up to $200 Mln- SEC Filing

THOMSON REUTERS
·
Aug 14

Rpt- Indaptus Therapeutics Inc Q2 EPS $-9.09

THOMSON REUTERS
·
Aug 13

Indaptus Therapeutics Q2 EPS $(9.09) Beats $(9.24) Estimate

Benzinga
·
Aug 13

Indaptus Therapeutics Initiates Phase 1b/2 Trial Combining Decoy20 With PD-1 Inhibitor Tislelizumab for Cancer Treatment

Reuters
·
Aug 13

Indaptus Therapeutics Inc. Held Special Meeting of Shareholders

Reuters
·
Jul 30

Indaptus Therapeutics Raises $3.4 Million in Additional Private Placement of Convertible Notes and Warrants

Reuters
·
Jul 01

BRIEF-Indaptus Therapeutics Announces Reverse Stock Split

Reuters
·
Jun 25

Indaptus Therapeutics Sells $2.3 Million of Convertible Notes, Warrants; Shares Fall Pre-Bell

MT Newswires Live
·
Jun 13

Indaptus Therapeutics Inc. Conducted Annual Meeting

Reuters
·
Jun 12

Indaptus Therapeutics Reports Q1 2025 Loss Per Share of $0.32, Improved from $0.45 in Q1 2024; R&D Expenses Rise to $2.8M

Reuters
·
May 14

Indaptus Therapeutics Says New Data on Decoy20 Shows Broad Immune System Activation in Cancer Patients

MT Newswires Live
·
Mar 20

Indaptus Therapeutics FY24 EPS $(1.61) Up From $($1.83) YoY

Benzinga
·
Mar 13

BRIEF-Indaptus Therapeutics reports full-year loss of $1.61 per share

Reuters
·
Mar 13